健康研究
健康研究
건강연구
HEALTH RESEARCH
2015年
1期
38-39,42
,共3页
慢性肾炎%阿托伐他汀%缬沙坦%尿蛋白%C反应蛋白
慢性腎炎%阿託伐他汀%纈沙坦%尿蛋白%C反應蛋白
만성신염%아탁벌타정%힐사탄%뇨단백%C반응단백
chronic nephritis%atorvastatin%valsartan%urine protein%C-reactive protein
目的:探讨缬沙坦联合阿托伐他汀治疗慢性肾炎的临床疗效。方法将168例慢性肾炎患者随机分入A组与B组,两组患者均接受慢性肾炎常规治疗。 A组患者同时接受口服缬沙坦,B组患者接受缬沙坦及阿托伐他汀口服,疗程12月。比较两组治疗前后肾功能、24 h尿蛋白定量、超敏C反应蛋白、肾小球滤过率( GFR)、血脂、血压、肝功能及肌酶等差别。结果治疗12个月后,B组hs-CRP、24h尿蛋白显著优于A组(P<0.05),B组胆固醇及低密度脂蛋白显著降低(P<0.05),两组收缩压、舒张压、肝功能、肌酶水平比较差异无统计学意义(P>0.05)。结论缬沙坦联合阿托伐他汀治疗慢性肾炎可显著降低CRP水平并减少尿蛋白,有利于延缓病情。
目的:探討纈沙坦聯閤阿託伐他汀治療慢性腎炎的臨床療效。方法將168例慢性腎炎患者隨機分入A組與B組,兩組患者均接受慢性腎炎常規治療。 A組患者同時接受口服纈沙坦,B組患者接受纈沙坦及阿託伐他汀口服,療程12月。比較兩組治療前後腎功能、24 h尿蛋白定量、超敏C反應蛋白、腎小毬濾過率( GFR)、血脂、血壓、肝功能及肌酶等差彆。結果治療12箇月後,B組hs-CRP、24h尿蛋白顯著優于A組(P<0.05),B組膽固醇及低密度脂蛋白顯著降低(P<0.05),兩組收縮壓、舒張壓、肝功能、肌酶水平比較差異無統計學意義(P>0.05)。結論纈沙坦聯閤阿託伐他汀治療慢性腎炎可顯著降低CRP水平併減少尿蛋白,有利于延緩病情。
목적:탐토힐사탄연합아탁벌타정치료만성신염적림상료효。방법장168례만성신염환자수궤분입A조여B조,량조환자균접수만성신염상규치료。 A조환자동시접수구복힐사탄,B조환자접수힐사탄급아탁벌타정구복,료정12월。비교량조치료전후신공능、24 h뇨단백정량、초민C반응단백、신소구려과솔( GFR)、혈지、혈압、간공능급기매등차별。결과치료12개월후,B조hs-CRP、24h뇨단백현저우우A조(P<0.05),B조담고순급저밀도지단백현저강저(P<0.05),량조수축압、서장압、간공능、기매수평비교차이무통계학의의(P>0.05)。결론힐사탄연합아탁벌타정치료만성신염가현저강저CRP수평병감소뇨단백,유리우연완병정。
Objective To examine the clinical effect of valsartan combined with atorvastatin in the treatment of chronic nephritis.Method 168 cases of chronic nephritis were randomly divided into two groups , group A and group B.Both groups were firstly given conventional treatment .Group A were treated with oral valsartan while group B were given valsartan and atorvastatin therapy .The length of treatment was 12 months.The change of renal function , 24h urine protein, hs-CRP, GFR, blood lipid, blood pressure, liver function and enzyme before and after treatment in the two groups were compared.Findings After treatment, hs-CRP and 24h urine protein in group B were superior to those in group A (P<0.05);TC and LDL-C after treatment in group B significantly decreased (P<0.05).No significant change was found in group A (P>0.05);The difference between the two groups in systolic pressure , diastolic pressure, liver function, muscle enzyme levels was not significant (P>0.05).Conclusion Valsartan combined with atorvastatin for chronic nephritis can greatly decrease the level of CRP and urine protein and delay the occurrence of disease .